← Eichor
Study identifier: NCT04715568 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Secondhand Tobacco Smoke and Cardiovascular Disease

Condition: Cardiovascular Diseases · Hypertension  ·  Sponsor: University of California, San Francisco

PhasePhase 4
Planned participants100
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

This description comes directly from the study's public registry record.

Talk to the study team

Mehrdad Arjomandi, MD  ·  (415)221-4810  ·  mehrdad.arjomandi@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

San Francisco Veterans' Affairs Medical CenterSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04715568